|
|
|
|
|
Teisinis statusas
Patentas galioja
| (51) | INT.CL. | C07D 401/14 | (2006.01) |
| A61K 31/506 | (2006.01) | ||
| A61P 3/00 | (2006.01) |
| (11) | Patento numeris | 3500564 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17761332.0 |
| Europos patento paraiškos padavimo data | 2017-08-09 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-06-26 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-10-07 |
| (46) | Apibrėžties vertimo paskelbimo data | 2020-12-28 |
| (86) | Numeris | PCT/IB2017/054862 |
| Data | 2017-08-09 |
| (87) | Numeris | WO 2018/033832 |
| Data | 2018-02-22 |
| (30) | Numeris | Data | Šalis |
| 201662377137 P | 2016-08-19 | US |
| (72) |
BOEHM, Markus, US
CABRAL, Shawn, US
DOWLING, Matthew S., US
FUTATSUGI, Kentaro, US
HUARD, Kim, US
LEE, Esther Cheng Yin, US
LI, Qifang, US
LONDREGAN, Allyn T., US
POLIVKOVA, Jana, US
PRICE, David A., US
|
| (73) |
Pfizer Inc. ,
66 Hudson Boulevard East, New York, NY 10001-2192,
US
|
| (74) |
Otilija KLIMAITIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Diacilglicerolio aciltransferazės 2 inhibitoriai |
| DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS |
| Mokėjimo data | Galiojimo metai | Suma | |
| 2024-07-12 | 8 | 185.00 EUR |
| 2025-08-09 |